tiprankstipranks
AC Immune Reveals Pioneering Neurodegenerative Drug Technology
Company Announcements

AC Immune Reveals Pioneering Neurodegenerative Drug Technology

AC Immune SA (ACIU) has released an update.

Don't Miss our Black Friday Offers:

AC Immune SA has introduced a groundbreaking antibody drug conjugate (ADC) technology, named morADC, at the Alzheimer’s Association International Conference, showcasing its potential to revolutionize treatment for neurodegenerative diseases. This novel technology leverages the company’s proprietary Morphomer small molecules and SupraAntigen monoclonal antibodies to create drug-candidates with enhanced brain penetration and potency against toxic proteins in the central nervous system. The morADC platform promises to offer unique, synergistic benefits, potentially overcoming limitations of current treatments and advancing precision medicine in neurodegenerative conditions.

For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAC Immune Q3 2024: Strong Progress and Financial Turnaround
TheFlyAC Immune reports interim results from Phase 2 trial of ACI-7104.056
TipRanks Auto-Generated NewsdeskAC Immune’s Promising Trial Results for Parkinson’s Therapy
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App